Oral Bioavailability of Peptide Therapeutics

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Peptides, defined as short sequences of amino acids, are gaining significant attention in clinical and preclinical research due to their therapeutic potential. Historically, the majority of peptide-based therapies required parenteral routes, particularly subcutaneous administration, to achieve clinical effectiveness. However, advances in molecular modification and formulation technologies have enabled certain peptides to be delivered orally with measurable systemic activity. This transition holds relevance for therapeutic accessibility, patient adherence, and safety.

Advantages of Oral Peptide Delivery

Patient Convenience
Oral administration eliminates the need for injections, allowing patients or research subjects to self-administer treatment without medical supervision. This reduces the burden of healthcare visits and addresses needle-related aversion.

Enhanced Absorption
Modifications in peptide structure or formulation, such as altering chain length or using alternative salt forms, have demonstrated improvements in gastrointestinal absorption. These changes increase systemic exposure, thereby potentially reducing the required therapeutic dose.

Reduced Injection-Related Adverse Events
Parenteral delivery is associated with local complications, including pain, swelling, and the risk of infection at the administration site. Oral formulations bypass these concerns, providing a safer alternative for some individuals.

Improved Treatment Adherence
Ease of use and decreased reliance on healthcare facilities contribute to higher compliance rates. Better adherence is expected to improve therapeutic outcomes in long-term treatment regimens.

Thymosin Beta-4 and Fragmented Derivatives

Background
Thymosin Beta-4 (commonly referenced as TB500 in research settings) is a naturally occurring peptide implicated in tissue repair, angiogenesis, and modulation of inflammation. Its therapeutic use has largely depended on subcutaneous delivery due to poor gastrointestinal stability and absorption.

Fragment SDKP and Oral Activity
A shortened derivative, the tetrapeptide sequence Ser–Asp–Lys–Pro (SDKP), demonstrates improved oral absorption compared to the parent peptide. Preclinical models indicate that SDKP achieves significantly higher systemic bioavailability, with oral absorption reported around 30% in rat studies, whereas TB500 showed negligible uptake (<1%). Furthermore, SDKP exhibited an extended half-life and improved pharmacokinetic exposure, supporting the hypothesis that structural modification can enhance oral peptide therapy viability.

BPC157: Influence of Salt Form on Oral Absorption

Therapeutic Profile
BPC157 is a synthetic peptide under investigation for its roles in gastrointestinal repair, musculoskeletal healing, and anti-inflammatory effects. Experimental evidence also suggests neuroprotective and potential antineoplastic properties.

Comparison of Salt Forms
Traditionally, BPC157 has been formulated as an acetate salt. Recent evaluations have explored the arginate salt as an alternative, showing markedly improved pharmacokinetics. In preclinical studies, oral administration of the arginate salt produced over sevenfold higher systemic exposure compared with the acetate salt in rat models. This finding emphasizes the clinical relevance of salt selection in optimizing peptide absorption, solubility, and stability.

Clinical Implications

Research indicates that both structural modification (e.g., peptide fragmentation) and formulation strategies (e.g., salt substitution) are effective in enhancing oral peptide delivery. These approaches expand the therapeutic potential of peptides beyond parenteral use, supporting improved patient comfort, compliance, and accessibility.

• Thymosin Beta-4 Fragment (SDKP): Demonstrates enhanced oral pharmacokinetics and retains biological activity in tissue repair and inflammation modulation.
• BPC157 Arginate Salt: Provides substantially higher oral absorption compared to the acetate salt form, suggesting improved clinical feasibility for oral delivery.

Conclusion

The development of orally bioavailable peptide therapeutics represents a critical step forward in translational medicine. While injectable administration remains a standard, advancements in peptide engineering and pharmaceutical formulation now allow select peptides to achieve therapeutic plasma concentrations via the oral route. These innovations reduce barriers to treatment, minimize adverse effects associated with injections, and hold promise for broader patient adherence. Ongoing research into absorption-enhancing strategies is likely to expand the therapeutic utility of peptide-based interventions across multiple clinical domains.

REFERENCES

1. Kassem, K. M., Vaid, S., Peng, H., Sarkar, S., & Rhaleb, N. E. (2019). Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?. Canadian journal of physiology and pharmacology, 97(7), 589–599. https://doi.org/10.1139/cjpp-2018-0570
2. He, L., Feng, D., Guo, H., Zhou, Y., Li, Z., Zhang, K., Zhang, W., Wang, S., Wang, Z., Hao, Q., Zhang, C., Gao, Y., Gu, J., Zhang, Y., Li, W., & Li, M. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in pharmacology, 13, 1026182. https://doi.org/10.3389/fphar.2022.1026182
3. Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural regeneration research, 17(3), 482–487. https://doi.org/10.4103/1673-5374.320969